Vertex Pharmaceuticals (NASDAQ:VRTX) has been on a roll so far in 2020. The big biotech delivered strong growth in the first quarter. It received a positive opinion from the European Medical Agency's Committee for Medicinal Products for Human Use regarding the potential approval of cystic fibrosis (CF) drug Kaftrio. And its shares have soared nearly 29% year to date.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,